FGF21 and metabolic dysfunction-associated steatohepatitis: FGF21 has emerged as the preferred therapeutic target FGF for metabolic diseases such as non-alcoholic steatohepatitis (NASH), metabolic syndrome, and diabetes mellitus (DM).